Matricelf Ltd. Logo

Matricelf Ltd.

Develops autologous, patient-specific tissue implants for regenerative medicine.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion

Description

Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matricelf Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ceres Power Holdings PLC Logo
A developer of solid oxide technology for clean power and green hydrogen production.
United Kingdom
CWR
Certara, Inc. Logo
Accelerates drug development using biosimulation software, technology, and services.
United States of America
CERT
CervoMed Inc. Logo
A clinical-stage biotech developing treatments for age-related neurologic disorders.
United States of America
CRVO
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and provides CDMO and bio-banking services.
South Korea
085660
CHAMPIONS ONCOLOGY, INC. Logo
A CRO providing end-to-end solutions to accelerate oncology drug development.
United States of America
CSBR
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Logo
A contract research organization supporting drug discovery and development.
United States of America
CRL
Chiome Bioscience Inc. Logo
Clinical-stage biotech company developing antibody-based therapeutics.
Japan
4583
Chordate Medical Holding AB Logo
Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.
Sweden
CMH
Chordia Therapeutics,Inc Logo
Clinical-stage biotech developing novel cancer therapies targeting RNA deregulation.
Japan
190A
Cibus, Inc. Logo
Develops and licenses plant traits using non-GMO precision gene-editing technology.
United States of America
CBUS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.